FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.
Key Details
- 1UltraSight's AI Echo Stewardship Platform now cleared by FDA for broader ultrasound compatibility.
- 2No new ultrasound equipment is required—compatible with handheld, laptop, and cart-based devices.
- 3Platform provides real-time, AI-assisted guidance for focused cardiac ultrasound (FoCUS) image acquisition.
- 4Aims to reduce variability and improve the usability of cardiac ultrasound by non-sonographer clinicians.
- 5Supports healthcare systems in scaling FoCUS exams without purchasing new hardware.
Why It Matters
By enabling AI-guided echocardiography on existing devices, this clearance lowers adoption barriers, expands cardiac imaging capabilities system-wide, and supports quality imaging by non-experts—potentially easing staff shortages and improving patient care accessibility.
Source
Cardiovascular Business
Related News
•Cardiovascular Business
FDA Clears AI Platform for Comprehensive Cardiac Risk Assessment on CT
HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.
•Radiology Business
FDA Clears Multi-Disease AI Screening Platform for CT Imaging
HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
•Radiology Business
FDA Approves 56 New AI Radiology Devices, Total Tops 1,000
FDA updates its list with 56 new AI-powered radiology devices, bringing the total to over 1,000 approved tools.